DAVID PERZ: Open Payments
NPI 1558450684 · HEMET, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,647 in 90 payments from 20 companies in 2025. Trend: 2023 $1,598 · 2024 $1,482 · 2025 $1,647
Food & beverage: $1,647
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 27 | $341 |
| AstraZeneca Pharmaceuticals LP | 9 | $260 |
| Xeris Pharmaceuticals, Inc. | 13 | $186 |
| RECORDATI_RARE_DISEASES_INC. | 8 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $145 |
| Merck Sharp & Dohme LLC | 3 | $86 |
| GlaxoSmithKline, LLC. | 3 | $57 |
| Lundbeck LLC | 2 | $51 |
| Amgen Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
Products named: Korlym, RECORLEV, ISTURISA, AIRSUPRA, CAPLYTA, REXULTI, FARXIGA, VERQUVO.
Industry payments across CA — which companies pay providers there.
